Belite Bio To Present Tinlarebant Data At Euretina

(RTTNews) - Tuesday, Belite Bio (BLTE) said it will present data from its retinal disease programs at two upcoming medical conferences in Vienna, including topline Phase 3 DRAGON study results for tinlarebant in adolescent Stargardt disease.

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A-derived bisretinoids linked to retinal damage in Stargardt disease.

The DRAGON study met its primary endpoint, and Belite Bio's FDA application for tinlarebant in Stargardt disease received priority review in August 2026. The FDA has set a PDUFA date of February 12, 2027.

Currently, BLTE is trading at $165.45, down 0.29%.